ELAN · Elanco Animal Health Inc · Documents

May 9

Earnings call

Q1 2022 earnings call

May 9

Current report 8-K

Financial results

May 9

Quarterly report 10-Q FY2022 Q1, ended Mar 31

Quarterly report for FY2022 Q1

Revenue $1.23B ▼ 1.4% Net income $48M Diluted EPS $0.10

Apr 20

Current report 8-K Events of Apr 19

Entered into a material agreement, New debt or off-balance-sheet obligation

Apr 13

Current report 8-K Events of Apr 11

Director or officer change, or executive pay, Regulation FD disclosure, Other events

Apr 6

Proxy statement DEF 14A Meeting May 18, 2022

Proxy statement

Apr 6

Proxy statement DEFA14A

Proxy statement

Mar 29

Current report 8-K

Regulation FD disclosure

Mar 24

Proxy statement PRE 14A Meeting May 18, 2022

Proxy statement

Feb 28

Annual report 10-K FY2021, ended Dec 31

Annual report for FY2021

Revenue $4.77B ▲ 45.6% Net loss $472M Diluted EPS -$0.97

Feb 24

Earnings call

Q4 2021 earnings call

Feb 24

Current report 8-K Events of Feb 22

Financial results, Charter or bylaw amendment, or fiscal year change

Jan 14

Current report 8-K Events of Jan 11

Other events

Jan 10

Current report 8-K

Financial results, Regulation FD disclosure

Jan 6

Current report 8-K Events of Jan 1

Director or officer change, or executive pay

Nov 30

Current report 8-K Events of Nov 29

Exit or restructuring costs, Regulation FD disclosure

Nov 5

Earnings call

Q3 2021 earnings call

Nov 5

Current report 8-K

Financial results

Nov 5

Quarterly report 10-Q FY2021 Q3, ended Sep 30

Quarterly report for FY2021 Q3

Revenue $1.13B ▲ 27.1% Net loss $104M Diluted EPS -$0.21

Oct 5

Current report 8-K

Director or officer change, or executive pay, Regulation FD disclosure

Aug 30

Current report 8-K Events of Aug 27

Regulation FD disclosure, Other events

Aug 12

Current report 8-K

Entered into a material agreement, New debt or off-balance-sheet obligation

Aug 9

Earnings call

Q2 2021 earnings call

Aug 9

Current report 8-K

Financial results

Aug 9

Quarterly report 10-Q FY2021 Q2, ended Jun 30

Quarterly report for FY2021 Q2

Revenue $1.28B ▲ 118.3% Net loss $210M Diluted EPS -$0.43

Aug 2

Current report 8-K Events of Jul 30

Other events

Jul 1

Current report 8-K Events of Jun 30

Entered into a material agreement

Jun 16

Current report 8-K Events of Jun 15

Entered into a material agreement, Regulation FD disclosure, Other events

Jun 9

Current report 8-K

Material impairment

Jun 4

Current report 8-K

Other events

May 21

Current report 8-K Events of May 19

Director or officer change, or executive pay, Shareholder vote results

May 7

Current report 8-K

Regulation FD disclosure

May 7

Earnings call

Q1 2021 earnings call

May 7

Current report 8-K

Financial results

May 7

Quarterly report 10-Q FY2021 Q1, ended Mar 31

Quarterly report for FY2021 Q1

Revenue $1.24B ▲ 88.8% Net loss $61M Diluted EPS -$0.12

Apr 8

Proxy statement DEFA14A

Proxy statement

Mar 25

Proxy statement DEF 14A Meeting May 19, 2021

Proxy statement

Mar 1

Annual report 10-K FY2020, ended Dec 31

Annual report for FY2020

Revenue $3.27B ▲ 6.6% Net loss $560.1M Diluted EPS -$1.27

Feb 24

Earnings call

Q4 2020 earnings call

Feb 24

Current report 8-K

Financial results

Feb 23

Current report 8-K Events of Feb 22

Other events

Jan 26

Current report 8-K Events of Jan 25

Exit or restructuring costs, Regulation FD disclosure

Jan 11

Current report 8-K

Other events

Dec 17

Current report 8-K

Other events

Dec 15

Current report 8-K Events of Dec 13

Director or officer change, or executive pay, Other events

Dec 15

Current report 8-K

Regulation FD disclosure

Dec 3

Current report 8-K Events of Nov 30

Other events

Dec 1

Current report 8-K Events of Nov 30

Regulation FD disclosure

Nov 30

Current report 8-K

Regulation FD disclosure

Nov 23

Current report 8-K Events of Nov 17

Director or officer change, or executive pay